News

The flu program is the first in programs leveraging BioNTech’s mRNA technology for vaccines for other respiratory viruses, oncology, and genetic diseases.

Effective Jan. 1 2022, the move brings the price to 2008 levels.

In the second part of an interview with Managing Editor Peter Wehrwein, Paulus talks about the role of PBMs and aligning providers with payers.

Judging by common end points such as overall survival and progression-free survival, results of a network meta-analysis show that Keytruda in combination with platinum-based chemotherapy achieves the best results among the immune checkpoint inhibitor therapies used to treat advanced nonsmall cell lung cancer.

The FDA has approved three targeted therapies for spinal muscular atrophy. They have hefty price tags so cost and affordability are live topics.

Prices paid by Veterans Affairs were the lowest and were 50% to 60% below list prices.

Digital-first experiences are commonplace for consumers today, with one exception—healthcare—where telehealth recently became just a stopgap. The pandemic has highlighted the real depth of this digital divide, especially when it comes to care coordination.

Pfizer receives an EUA for its COVID-19 booster, a biosimilar of Lucentis to treat macular degeneration is approved, Incyte receives two approvals for JAK inhibitors, one for atopic dermatitis and another for GVHD, and more FDA news.

In a study conducted by JAMA, results were recently released sharing children with active asthma had reduced symptom days, but not significantly, in the use of a school-wide integrated pest management program or a high-efficiency particulate air filter purifier in recorded 2-week time periods.

Paulus, a relative newcomer to the industry, discusses the advantages of having a fresh perspective, the complexity of the industry, rebates, and big employers pushing for more transparency.

A company developing a new therapy for hypertrophic cardiomyopathy released data recently showing that people with the obstructive form of the disease often develop hypertension, atrial fibrillation and other forms of cardiovascular disease.

In this week's episode of Tuning In to the C-Suite podcast, Briana Contreras of MHE chatted with Daniel Drake, president and CEO of Trinity Health PACE, or Programs of All-Inclusive Care for the Elderly. Dan and Briana discussed the specifics of how PACE has grown in recent years, the outlook for these programs in the future and how PACE is benefitting older patients’ wellbeing and their healthcare costs.

Black HCM patients were more likely than White HCM patients to have mid-ventricular obstruction, according to recently reported findings.

Three experts say that pulmonary rehabilitation programs don’t necessarily result in improved lung function but are associated with improved physical and other sorts of functioning. Less than 5% of those who might benefit from pulmonary rehabilitation services received them.

People over the age 65 and those at high risk of severe COVID-19, including health care workers and those with occupational exposure, are eligible for the booster.

The next step is for the CDC's Advisory Committee on Immunization Practices to make a decision on whether to add a COVID-19 booster to its recommendations

Dr. Reddy’s has also launched a generic of Librax. Recent generic approvals include clindamycin phosphate foam and sodium acetate.

Copays and formulary tiers involve financial incentives to use certain drugs. But is Cigna’s offer of a $500 debit card in a different category?

Exact Sciences test that uses DNA methylation biomarkers is more sensitive than alpha-fetoprotein.

A recent City of Hope study claims a therapy that combines a drug that disrupts DNA repair with chemotherapy cisplatin and gemcitabine does not prolong progression-free survival for patients with urothelial cancer.

The Association for Accessible Medicines said biosimilar drugs saved $7.9 billion in 2020, more than tripling the $2.5 billion saved in 2019.

Research has linked many drugs to QT prolongation and decision support tools could alert clinicians to the risk and guide prescribing decisions to safer alternatives.

A recent study reveals longstanding innovation operation issues create a deep-seated risk to corporate growth performance.

The drug won't be available till next year but is expected to dent sales of Roche's blockbuster for age-related macular degeneration and other eye diseases.

Medical decision-making is challenging given the quantity of data and volume of evidence that exists. To overcome traditional barriers and deliver on the full promise of clinical decision support, practices should consider cloud-based composable platforms that bring leverage advancements in interoperability.

The organization expands existing initiatives to address systemic inequities with long-term, collaborative focus on community-based programs for serious chronic illness patients.

While there was a noticeable surge in telehealth usage during the global pandemic, broadband coverage has only increased by about 10%.

Advisory panel endorses Pfizer vaccine booster for some, Brukinsa gets third indication, oral migraine med makes headway and other FDA-related news this week.